Immunic Inc
https://www.immunic-therapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immunic Inc
Top 10 Things To Watch For At DDW
At Digestive Disease Week, Celltrion will seek to strengthen its hold on the IBD market, Ironwood hopes to expand Linzess into pediatric functional constipation, and competitors will showcase competing short bowel syndrome treatment and colorectal cancer companion diagnostics.
Immunic Doubles Down On Lead Asset With New Data In Ulcerative Colitis
The company is emphasizing development of vidofludimus calcium in multiple indications and deprioritizing izumerogant, an asset the company was developing in psoriasis and prostate cancer.
Immunic Psoriasis Analysis Adds Dose Of Uncertainty To Program
Without disclosing full Phase Ib data, the company reported a higher-than-expected placebo response versus IMU-935. With its second setback this year Immunic has a long path to meaningful data.
Deal Watch: Lilly, Innovent Build On Long Alliance To Partner On Three Cancer Drugs
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Immunic AG
- Immunic Therapeutics
- Vital Therapies, Inc. (VTL)
- Immunic, Therapeutics.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice